Global Pharmatech Stock Analysis
| GBLP Stock | USD 0.05 0.00 0.00% |
Global Pharmatech holds a debt-to-equity ratio of 0.285. Global Pharmatech's financial risk is the risk to Global Pharmatech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Global Pharmatech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Global Pharmatech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Global Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Global Pharmatech's stakeholders.
For many companies, including Global Pharmatech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Global Pharmatech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Global Pharmatech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Global Pharmatech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Global Pharmatech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Global Pharmatech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Global Pharmatech is said to be less leveraged. If creditors hold a majority of Global Pharmatech's assets, the Company is said to be highly leveraged.
Global Pharmatech is overvalued with Real Value of 0.042 and Hype Value of 0.05. The main objective of Global Pharmatech pink sheet analysis is to determine its intrinsic value, which is an estimate of what Global Pharmatech is worth, separate from its market price. There are two main types of Global Pharmatech's stock analysis: fundamental analysis and technical analysis.
The Global Pharmatech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Global |
Global Pink Sheet Analysis Notes
The company has price-to-book (P/B) ratio of 0.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Global Pharmatech recorded a loss per share of 0.1. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of February 2005. Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China. Global Pharmatech operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 217 people.The quote for Global Pharmatech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Global Pharmatech call the company at 86 431 8554 1826 or check out http://www.global-pharmatech.com.Global Pharmatech Investment Alerts
| Global Pharmatech generated a negative expected return over the last 90 days | |
| Global Pharmatech has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 2.82 M. Net Loss for the year was (3.3 M) with profit before overhead, payroll, taxes, and interest of 1.32 M. | |
| Global Pharmatech currently holds about 5.44 M in cash with (383.94 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Global Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.42 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Global Pharmatech's market, we take the total number of its shares issued and multiply it by Global Pharmatech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Global Profitablity
The company has Profit Margin (PM) of (0.7) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.73.Technical Drivers
Global Pharmatech technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Global Pharmatech Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Triangular Moving Average shows Global Pharmatech double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
Global Pharmatech Outstanding Bonds
Global Pharmatech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Global Pharmatech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Global bonds can be classified according to their maturity, which is the date when Global Pharmatech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| GPN 215 15 JAN 27 Corp BondUS37940XAG79 | View | |
| GPN 29 15 NOV 31 Corp BondUS37940XAH52 | View | |
| Global Payments 32 Corp BondUS37940XAB82 | View | |
| Global Payments 415 Corp BondUS37940XAC65 | View | |
| GLOBAL PAYMENTS INC Corp BondUS37940XAD49 | View | |
| GLOBAL PAYMENTS INC Corp BondUS37940XAE22 | View | |
| GPN 495 15 AUG 27 Corp BondUS37940XAP78 | View |
Global Pharmatech Debt to Cash Allocation
Global Pharmatech currently holds 2.62 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Global Pharmatech has a current ratio of 1.82, which is within standard range for the sector. Debt can assist Global Pharmatech until it has trouble settling it off, either with new capital or with free cash flow. So, Global Pharmatech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Pharmatech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Pharmatech's use of debt, we should always consider it together with cash and equity.Global Pharmatech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Global Pharmatech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Global Pharmatech, which in turn will lower the firm's financial flexibility.Global Pharmatech Corporate Bonds Issued
About Global Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Global Pharmatech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Global shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Global Pharmatech. By using and applying Global Pink Sheet analysis, traders can create a robust methodology for identifying Global entry and exit points for their positions.
Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China. Global Pharmatech operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 217 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Global Pharmatech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Additional Tools for Global Pink Sheet Analysis
When running Global Pharmatech's price analysis, check to measure Global Pharmatech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Global Pharmatech is operating at the current time. Most of Global Pharmatech's value examination focuses on studying past and present price action to predict the probability of Global Pharmatech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Global Pharmatech's price. Additionally, you may evaluate how the addition of Global Pharmatech to your portfolios can decrease your overall portfolio volatility.